LIMIT Trial - Lidocaine With Intramuscular Injection of Benzathine Penicillin G for Treponema Pallidum Treatment
Study acronym: LIMIT
StatusRecruiting
PhasePhase 3
Started2024-07-01
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 25, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
There is evidence to suggest that lidocaine can help reduce the pain associated with intramuscular injections of benzathine penicillin G (BPG) or Bicillin, used to treat syphilis infections. A study published in the Journal of Family Practice in 2001 compared the pain experienced during bicillin injections with and without the use of lidocaine. The study found that patients who received lidocaine injections before receiving bicillin reported significantly less pain compared to those who received bicillin injections without lidocaine. Per the International Union against Sexually Transmitted Infections (IUSTI) European Guidelines for syphilis management, lidocaine has been used as a diluent for BPG since 1998. In the United States (US), BPG often comes prepackaged and lidocaine is unable to be used as a diluent with the same ease as it is in Europe. In light of this, the investigators propose a randomized controlled trial of benzathine penicillin G with and without lidocaine to quantify any site pain reduction with lidocaine in patients being treated for syphilis.
This study is a randomized, double blinded, placebo controlled trial. During this study, patients needing BPG treatment for syphilis will be screened for any penicillin allergies and consented to their participation. Each participant will receive 2 injections of BPG, 1.2 million units each (2x1.2 million units = 2.4 million units, the standard dose for syphilis treatment), as intramuscular injections, one in each gluteal muscle, with one of the injections randomly having 0.5ml of 1% lidocaine added while the other has 0.5 ml normal saline solution. The side of each injection will be randomized by the medical assistant (MA)/nurse filling the vials and the injecting MA will be blinded, as well as the study participant, as to which vial contains lidocaine and which contains normal saline. The participants will then be asked to rate their pain from 0-10 on each site of injection at 10 minutes post injection, then again at 24 hours after injection via email electronic survey (via RedCap). The differences in pain from the two injections will be compared and analyzed to see if lidocaine reduces pain associated with BPG injections compared to the control of normal saline added to BPG.
Amendment record
Amended 2 times since 2024-04-27; most recent filed 2025-03-24. Every amendment is listed below.
Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-29.
2025-03-24
Amendment Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
2024-07-22
Amendment Study Status, Study Description v1
2024-04-27
Original filing
| NCT Number |
NCT06391125 |
| Lead Sponsor |
Washington University School of Medicine
|
| Conditions |
Syphilis Infection, Benzathine Penicillin Adverse Reaction |
| Enrollment |
48 participants |
| Start Date |
2024-07-01 |
| Primary Completion |
2025-12 (estimated) |
| Study Completion |
2025-12 (estimated) |
| Updated on ClinicalTrials.gov |
2025-03-25 |